M&A Deal Summary |
|
|---|---|
| Date | 2025-12-09 |
| Target | Staccato OBT |
| Sector | Life Science |
| Buyer(s) | Lee’s Pharmaceutical |
| Sellers(s) | Alexza Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
Lee’s Pharmaceutical is a biopharmaceutical company engaged in the research, development, manufacturing, marketing, and sale of pharmaceutical products across multiple therapeutic areas, including cardiovascular diseases, infectious diseases, oncology, dermatology, women’s health, and ophthalmology. The Company’s business integrates R&D, clinical development, regulatory approval, manufacturing, and distribution, and includes both proprietary and licensed-in products sold in Mainland China, Hong Kong, Macau, and Taiwan. Lee’s Pharmaceutical was founded in 1994 and is based in Hong Kong.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Life Science |
| Employees | 28 |
| Revenue | 5M USD (2015) |
Alexza Pharmaceuticals, Inc. is a developer of drugs for acute and intermittent medical conditions. Their Staccato system aerosolizes without thermal degradation, enabling convenient delivery and rapid therapeutic onset of many small molecule drugs.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-08-26 |
Symphony Allegro
Rockville, Maryland, United States Symphony Allegro, Inc. is a biopharmaceutical company. |
Buy | - |
